News Justin Yang, Biomedical Advanced Research and Development Authority (BARDA) Director of the DRIVe Catalyst Office, Joins Rich Bendis on BioTalk BARDA Director of the DRIVe Catalyst Office, Justin Yang, Joins BioTalk to share how BARDA…Super UserOctober 14, 2020
BHI Weekly News Archives 427th Edition, October 13, 2020 BioHealth Innovation If you are having trouble viewing this email, please click here October 12,…Super UserOctober 13, 2020
News How This Med Tech Startup Pivoted to Fight the Pandemic Across the world in 2019, UNICEF reports that over 2.4 million infants died in their…Super UserOctober 12, 2020
News Children’s National Hospital earns 2020 CHIME Digital Health Most Wired recognition | Children’s National Hospital Children’s National Hospital has received 2020 Digital Health Most Wired recognition by The College of…Super UserOctober 12, 2020
News FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease – BioHealth Capital Region ROCKVILLE, Md.–(BUSINESS WIRE)–Oct. 5, 2020– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA)…Super UserOctober 12, 2020
News The unsung mapmakers | Hub In the early days of managing the Johns Hopkins COVID-19 dashboard, experts at the university…Super UserOctober 12, 2020
News Life Sciences Go Viral in Maryland When Maryland Gov. Larry Hogan visited Novavax recently, President and CEO Stanley C. Erck shared…Super UserOctober 12, 2020
News Qiagen to Complement COVID-19 Testing Portfolio with Novel Kit That Simplifies and Accelerates PCR Analysis for Research – COVID-19 – Hospimedica.com QIAGEN N.V. (Venlo, Netherlands) plans to launch a novel straightforward approach to viral RNA epidemiology…Super UserOctober 12, 2020
News Baltimore venture capital firm Catalio Capital Management closes $100M fund – Baltimore Business Journal Catalio's portfolio includes many notable local biotech companies, including Personal Genome Diagnostics Inc. and Thrive…Super UserOctober 12, 2020
News First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma GAITHERSBURG, MD -- October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio…Super UserOctober 12, 2020